Drugs that reduce the activity of an enzyme called phosphodiesterase 5A (PDE5A) are used worldwide as safe and efficacious agents for erectile dysfunction in older men, in men with diabetes, and in men with prostate cancer following therapy. Our recent finding in mice that the drugs also increase bone mass, particularly in females, has prompted our current investigations into their efficacy and mechanism of action. These preclinical studies, comprising both genetic and pharmacological approaches, should provide the basis for future clinical trials for osteoporosis in elderly women and men.
|Effective start/end date||1/05/21 → 28/02/23|
- National Institute on Aging: $693,892.00
- National Institute on Aging: $623,273.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.